SEC Form 4 · accession 0001209191-18-052076
Audentes Therapeutics, Inc. · BOLD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew R Patterson
Officer — Chief Executive Officer · Director
Period of report
Sep 24, 2018
Accepted (ET)
Sep 24, 2018 · 6:12 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001628738
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 24, 2018 | M | 15,000 | $0.78 | A | 15,000 | D | |
| Common StockF1 | holding | — | — | — | 171,814 | I | By Matthew R. Patterson Revocable Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $0.78 | Sep 24, 2018 | M | 15,000 | D | — | Sep 25, 2023 | Common Stock | 15,000 | 92,702 | D |
Explanation of responses
- F1The reporting person is the trustee of the Matthew R. Patterson Revocable Trust.
- F2The option vested as to 25% of the total shares on January 1, 2014, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on January 1, 2017, subject to the reporting person's provision of service to the issuer on each vesting date and to accelerated vesting in the event of the occurrence of certain events.